CONNEQT Launches Reports CardieX Limited

CardieX Limited (ASX: CDX), a global health technology company focused on hypertension, cardiovascular disease, and vascular health disorders, today announced CONNEQT™, a new consumer health company that will focus on home vital signs monitors, wearables, and consumer health apps.

Under the CONNEQT brand, CardieX is on track to launch multiple new devices and digital products to the market over the next twelve months.

Upcoming products include the CONNEQT “Pulse” – a dual blood pressure monitor anticipated to be the first consumer vital signs monitor to include central blood pressure and the company’s patented SphygmoCor® technology. In addition, the company is developing a new health wearable, the CONNEQT Band, which includes a full suite of patented health parameters as well as a comprehensive ecosystem of unique health and wellness features focused on heart health.

“Our goal with the development of a new brand for our consumer health products was to create an emotional connection and brand recognition to compete with leaders in the field such as Fitbit, Apple, Google Health, Peloton, Whoop, Garmin, and others,” said Craig Cooper, CEO and Co-founder of CardieX. “We believe that CONNEQT will disrupt health and fitness devices in the same way Beats disrupted Bose, Warby Parker disrupted the eyeglass industry, and Instagram disrupted photo sharing.”

Cooper stated, “We are uniquely positioned to be a strong market entrant into the $US100B health wearables market given our focus on vascular and heart health – the world’s #1 killer.”

Last week CardieX was granted another US patent for blood pressure measurement technology for “Non-Invasive Brachial Blood Pressure Measurement” which will remain in force until 2038. The company also holds over 14 patents in blood pressure and wearable sensor technologies which are being incorporated into their new CONNEQT devices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”